» Articles » PMID: 17708462

The Relationship Between Subjective Assessment Instruments in Chronic Rhinosinusitis

Overview
Journal Rhinology
Date 2007 Aug 22
PMID 17708462
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Problem: To provide an evidence-based definition for the relationship between three subjective instruments for assessing severity of chronic rhinosinusitis- visual analogue scale, 'mild' 'moderate' and 'severe' (MMS) classification and perception of whether quality of life (QoL) is affected.

Method Of Study: One hundred sixteen subjects with chronic rhinosinusitis filled in a questionnaire rating simultaneously their perception of disease severity based (1) upon visual analogue scale, (2) MMS classification and (3) stating whether they felt their QoL was affected.

Main Results: The mean age of subjects was 50. The inter-quartile range of VAS scores for the respective MMS groups were: Mild 0.80-3.50, Moderate 4.40-6.33, Severe 7.70-9.50. In the group who perceived effects on QoL, the inter-quartile range for VAS scores was 5.10-8.68. This range was 1.53-4.57 in the other group with no effects on QoL. 30.3% of patients in the 'mild' category, 79.6% in the 'moderate' category and 97.4% in the 'severe' category felt that their QoL was affected.

Principle Conclusions: We propose a statistically validated definition of the relationship between MMS classification and VAS scoring. Based on our study we would define 'mild' as being 0- 3 inclusive, 'moderate, as > 3- 7 inclusive and 'severe' as > 7- 10 inclusive on the VAS scoring system. We further propose that in general QoL is more likely to be affected with VAS scores of 5 or more.

Citing Articles

Patient perspectives on international multidisciplinary consensus criteria for chronic rhinosinusitis disease control.

Cotter R, Houssein F, Reinert R, Phillips K, Sedaghat A Laryngoscope Investig Otolaryngol. 2024; 9(5):e70005.

PMID: 39281205 PMC: 11401240. DOI: 10.1002/lio2.70005.


Patient-reported disease control versus overall symptom severity as global metrics of chronic rhinosinusitis disease status.

Cotter R, Garcia J, Alsayed A, Schneider S, Liu D, Eckl-Dorna J Int Forum Allergy Rhinol. 2024; 15(1):27-35.

PMID: 39269197 PMC: 11697220. DOI: 10.1002/alr.23435.


Analysis of Prevalence and Predictive Factors of Long-Lasting Olfactory and Gustatory Dysfunction in COVID-19 Patients.

Callejon-Leblic M, Martin-Jimenez D, Moreno-Luna R, Palacios-Garcia J, Alvarez-Cendrero M, Vizcarra-Melgar J Life (Basel). 2022; 12(8).

PMID: 36013436 PMC: 9410278. DOI: 10.3390/life12081256.


Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis.

Han J, Bachert C, Lee S, Hopkins C, Heffler E, Hellings P Laryngoscope. 2021; 132(2):265-271.

PMID: 34850966 PMC: 9299621. DOI: 10.1002/lary.29888.


Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.

Fujieda S, Matsune S, Takeno S, Ohta N, Asako M, Bachert C Allergy. 2021; 77(1):186-196.

PMID: 33993501 PMC: 9290136. DOI: 10.1111/all.14906.